Atopic Dermatitis Therapeutics
1. Anzupgo patent expiration
Treatment: Method of inhibiting janus kinase 2 or janus kinase 3 to treat moderate to severe chronic hand eczema (che) in adults who have had an inadequate response to, or for whom topical corticosteroids are no...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8609647 | LEO PHARMA AS | NA |
Sep, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2030 |
Drugs and Companies using DELGOCITINIB ingredient
NCE-1 date: 23 July, 2029
Market Authorisation Date: 23 July, 2025
Dosage: CREAM
More Information on Dosage
ANZUPGO family patents
2. Cibinqo patent expiration
Treatment: Treatment of adults with refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products or whe...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9035074 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(8 years from now) | |
| US9545405 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9549929 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Feb 09, 2026 |
| New Chemical Entity Exclusivity(NCE) | Jan 14, 2027 |
Drugs and Companies using ABROCITINIB ingredient
NCE-1 date: 14 January, 2026
Market Authorisation Date: 14 January, 2022
Dosage: TABLET
More Information on Dosage
CIBINQO family patents
3. Elidel patent
expiration
Treatment: NA
ELIDEL IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5912238 (Pediatric) | BAUSCH | Heteroatoms-containing tricyclic compounds |
Dec, 2016
(9 years ago) | |
|
US6352998 (Pediatric) | BAUSCH | Pharmaceutical compositions |
Apr, 2016
(9 years ago) | |
| US5912238 | BAUSCH | Heteroatoms-containing tricyclic compounds |
Jun, 2016
(9 years ago) | |
| US6352998 | BAUSCH | Pharmaceutical compositions |
Oct, 2015
(10 years ago) | |
|
US6423722 (Pediatric) | BAUSCH | Crystalline macrolides and process for their preparation |
Dec, 2018
(7 years ago) | |
| US6423722 | BAUSCH | Crystalline macrolides and process for their preparation |
Jun, 2018
(7 years ago) | |
Drugs and Companies using PIMECROLIMUS ingredient
Market Authorisation Date: 13 December, 2001
Dosage: CREAM
More Information on Dosage
ELIDEL family patents
4. Eucrisa patent expiration
Treatment: Method of treating mild to moderate atopic dermatitis.
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8039451 | ANACOR PHARMS INC | Boron-containing small molecules |
Jun, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8501712 | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Feb, 2027
(1 year, 1 month from now) | |
| US9682092 | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Feb, 2027
(1 year, 1 month from now) | |
| US8168614 | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Jan, 2030
(4 years from now) | |
|
US8039451 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Dec, 2029
(3 years from now) | |
|
US8168614 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Jul, 2030
(4 years from now) | |
|
US8501712 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Aug, 2027
(1 year, 7 months from now) | |
|
US9682092 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Aug, 2027
(1 year, 7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2021 |
| New Patient Population(NPP) | Mar 23, 2023 |
| Pediatric Exclusivity(PED) | Sep 23, 2023 |
| New Dosing Schedule(D-191) | Apr 03, 2026 |
Drugs and Companies using CRISABOROLE ingredient
NCE-1 date: 23 September, 2022
Market Authorisation Date: 14 December, 2016
Dosage: OINTMENT
How can I launch a generic of EUCRISA before it's drug patent expiration?
More Information on Dosage
EUCRISA family patents